Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III VIS513 versus placebo for symptomatic dengue
ISRCTN50970152Phase 3Recruiting
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in dengue fever comparing VIS513 with Matching placebo (2 arms). Primary endpoint: Time to sustained recovery. Started Aug 2026; status: recruiting.
02
Drugs
VIS513
03
Conditions
dengue fever
Beyond the preview
Go deeper on ISRCTN50970152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50970152.